An immunoliposome targeting ganglioside GD2 and mitochondria, and a preparation method and application thereof

CN117281775BActive Publication Date: 2026-06-09GUILIN MEDICAL UNIVERSITY

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
GUILIN MEDICAL UNIVERSITY
Filing Date
2023-10-08
Publication Date
2026-06-09

Smart Images

  • Figure CN117281775B_ABST
    Figure CN117281775B_ABST
Patent Text Reader

Abstract

The application belongs to the technical field of biological medicine, and particularly relates to an immune liposome targeting ganglioside GD2 and mitochondria as well as a preparation method and application thereof. The application couples LX3 and thiolated daratumumab to DSPE-PEG2000 respectively to obtain DSPE-PEG2000-LX3 and DSPE-PEG2000-aGD2, and then is compounded with DSPC and cholesterol to obtain the immune liposome, which has good dispersity, excellent stability and cannot induce cytotoxicity. Cell combination and uptake analysis shows that the immune liposome can specifically target ganglioside GD2 positive tumor cells and then further reach mitochondria thereof. Compared with existing liposomes, the immune liposome provided by the application has double targeting functions of ganglioside GD2 and mitochondria, and can selectively deliver an anti-tumor drug into mitochondria of neuroblastoma cells.
Need to check novelty before this filing date? Find Prior Art